Etoricoxib

• Description :

  Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

• Product Name Alternative :

  MK-0663; L-791456

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H310

• Target :

  COX

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Etoricoxib.html

• Purity :

  99.86

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=S(C1=CC=C(C2=CC(Cl)=CN=C2C3=CC=C(C)N=C3)C=C1)(C)=O

• Molecular Formula :

  C18H15ClN2O2S

• Molecular Weight :

  358.84

• Precautions :

  H302, H310

• References & Citations :

  [1]Riendeau D, et al.Etoricoxib (MK-0663) : preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296 (2) :558-66.|[2]Kunak CS, et al. The Effect of Etoricoxib on Hepatic Ischemia-Reperfusion Injury in Rats. Oxid Med Cell Longev. 2015;2015:598162.|[3]Tanwar L, et al. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11 (5) :1329-33.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  COX-1; COX-2

• CAS Number :

  [202409-33-4]